Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 19/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 11/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 11/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 11/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453196 | 0.81 | PIK3CA (0.78) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL4679525 | 0.78 | MAPK1 (0.60) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL5443639 | 0.76 | MAPK1 (0.47) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL12970824 | 0.75 | MAPK1 (0.80) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL5623238 | 0.74 | PIK3CA (0.70) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL3638708 | 0.74 | PIK3CA (0.72) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL4739232 | 0.74 | MAPK1 (0.52) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL5622765 | 0.73 | PIK3CA (0.74) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL14506574 | 0.72 | MAPK1 (0.75) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL5622692 | 0.72 | MAPK1 (0.64) | MAPK1PIK3CAMAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123494-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | ZENTARIS GMBH (DE) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123494-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | PLPBP, PDXK, MAP4K2 | MAPK1 58/4885PIK3CA 866/4885MAPK8 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.